flosz schreef:
Testing in Africa
The U.K.'s government-funded Medical Research Council began testing Mosquirix in adults in Gambia in 1998.
By 2002, the studies had expanded to include adolescents in Mozambique. One clinical trial, published in the British medical journal The Lancet in October, showed that infants between 10 and 18 weeks old had no ill effects from taking Mosquirix.
The shot also reduced new malaria infections in the first three months by 65 percent.
That isn't good enough to interest the U.S. military, which needs 99 percent effectiveness for soldiers, said Ballou, who now works for the Gates foundation.
Doctors treating malaria patients in Africa have a different perspective.
``If you can reduce 50 percent of the burden, then you reduce a lot of the burden faced by families and the health facilities,'' said Marcel Tanner, director of the Swiss Tropical Research Institute in Basel, Switzerland.
Cohen and his colleagues hope to know within three years whether they've won the race to produce an effective vaccine.
Creating Mosquirix was ``a huge milestone,'' said Alan Brooks, director of policy for the Malaria Vaccine Initiative, a charity based in Bethesda, Maryland, that has collaborated with Glaxo since 2001. ``This is the best hope for a first generation product.''
www.bloomberg.com/apps/news?pid=20601...*****************************************
Vaccine. 2008 Apr 16
Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.
Falciparum malaria vaccine candidates have been developed using recombinant, replication-deficient serotype 5 and 35 adenoviruses (Ad5, Ad35) encoding the Plasmodium falciparum circumsporozoite surface protein (CSP) (Ad5.CS, Ad35.CS) (Crucell Holland BV, Leiden, The Netherlands). To evaluate the immunogenicity of these constructs, BALB/cJ mice were immunized twice with either Ad5.CS, Ad35.CS, empty Ad5-vector (eAd5), empty Ad35 vector (eAd35), or saline. Another group received the CSP-based RTS,S malaria vaccine formulated in the proprietary Adjuvant System AS01B (GlaxoSmithKline Biologicals, Rixensart, Belgium). Here we report that Ad5.CS, Ad35.CS, and RTS,S/AS01B, elicited both cellular and serologic CSP antigen-specific responses in mice. These adenoviral vectors induce strong malaria-specific immunity and warrant further evaluation.
PMID: 18455276
www.ncbi.nlm.nih.gov/pubmed/18455276?...Uit post aossa, okt. 2007:
Is het geen noodzaak dat Crucell vaccine tesamen met het GSK wordt ontwikkeld en/of goedgekeurd. Eens het Ad35 van Crucell stand-alone goedgekeurd, zou het in een combinatie 'extended application' extra waarde (betere immuun respons) kunnen geven aan het GSK RTS, S vaccine, waarbij het Ad35 vaccine als eerste wordt toegediend en de T-cel immuniteit activeert ten voordele van de 2 volgende inentingen met het GSK vaccine. Respons >90% ipv 65% !
Meer via:
crucell.yourbb.nl/viewtopic.php?f=7&t...www.iex.nl/forum/topic.asp?forum=228&...